Genedata

Venture Valuation conducts an independent valuation of Genedata, a Swiss start-up company in order to help Novartis Venture Fund analyze and structure the next financing round. Venture Valuation, under a tight investment timeframe, has to customize the evaluation process, using both quantitative and qualitative data, to meet the customers needs. The case outlines Genedata’s background, its product portfolio, competitive positioning, and issues that it will need to deal with in the near future. Learning Objective: This case is part of a three case series intended to draw the audience into the issues surrounding the valuation of a startup biotechnology company, one of the most speculative and volatile marketplace.